Axogen Announces Promotions on Research and Development Team - Seite 2

• Stacy Arnold to Vice President of Product Development and Clinical Research   
  
  Ms. Arnold has served as Vice President of Clinical Research for Axogen since June 2019. She initially joined Axogen in April 2018 as Vice President of Program Management. She has been leading the research, development, and execution of clinical strategies to strengthen and advance the body of evidence for new technologies and clinical applications to restore nerve function and quality of life to patients with peripheral nerve injuries. Ms. Arnold previously served as Senior Director of R&D and Program Management at Artivion (formerly CryoLife), driving global innovation and new product development of medical devices, biologics, and tissue technologies, while leading successful program management processes and business strategies to drive growth and deliver shareholder value. Ms. Arnold serves as a Board Member on Mercer University’s National Engineering Advisory Board. She has an M.S. in Engineering from the University of Toledo and a B.S. in Biomedical Engineering from Mercer University. She also holds a global Project Management Professional Certification from the Project Management Institute.
  

In addition, the Company is announcing the departure of Angelo Scopelianos, Ph.D., Axogen’s Chief Research and Development Officer, in the first quarter of 2024.

“We want to thank Angelo for his contributions in new programs that led to innovations like the launch of Axoguard HA+ Nerve Protector^TM and the upcoming launch of Avive+ Soft Tissue Matrix^TM and we are pleased to announce the internal promotions of these leaders in our research and development team,” said Karen Zaderej, Axogen’s Chairman, CEO and President. “This is a strong, highly accomplished group that has worked together closely for many years and demonstrated great success in supporting our mission of improving the lives of patients with peripheral nerve injuries. The continuity of this expert team will also be important to Axogen as we move through the BLA submission process of Avance Nerve Graft toward the next commercial phase of our business as a biologic.